Literature DB >> 8883416

Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues.

Y Ito1, T Kobayashi, T Takeda, Y Komoike, E Wakasugi, Y Tamaki, M Tsujimoto, N Matsuura, M Monden.   

Abstract

p21 (WAF1/CIP1) protein expression in various thyroid tissues, including thyroid carcinoma, was studied by means of immunohistochemistry using anti-p21 monoclonal antibody. Normal follicles and hyperplasias rarely expressed p21, whereas immunohistochemically positive cells were also too rarely found in follicular adenomas to justify these cases being classified as positive. Twenty eight of the 93 carcinomas examined (30.1%), however, were positive for p21. Of the p21-positive cases, 80% of the undifferentiated and 28.6% of the poorly differentiated carcinomas showed lesions co-expressing p21 and p53. If diffuse immunoreactivity of p53 reflects the p53 mutation, our results indicate that p21 in these carcinomas can be induced by p53-independent as well as by p53-dependent pathways. On the other hand, well-differentiated carcinomas did not co-express these two proteins and it therefore remains unclear whether p53-independent or p53-dependent pathways are predominant in this type of carcinoma. The incidence of expression of p21 was very similar in undifferentiated (26.3%), poorly (28.0%) and well-differentiated carcinomas (32.7%), even though they are characterised by different degree of malignancy. Furthermore, no correlation between p21 expression and either clinical parameters or patient's prognosis could be established. These results suggest that p21 is only marginally related to the characteristics of thyroid carcinoma and can play only an adjuvant role in regulating the progression of this carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8883416      PMCID: PMC2075930          DOI: 10.1038/bjc.1996.528

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

2.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

3.  Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma".

Authors:  M L Carcangiu; G Zampi; J Rosai
Journal:  Am J Surg Pathol       Date:  1984-09       Impact factor: 6.394

4.  Increased levels of p21WAF1/Cip1 in human brain tumors.

Authors:  J M Jung; J M Bruner; S Ruan; L A Langford; A P Kyritsis; T Kobayashi; V A Levin; W Zhang
Journal:  Oncogene       Date:  1995-11-16       Impact factor: 9.867

5.  Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.

Authors:  P A Wright; N R Lemoine; P E Goretzki; F S Wyllie; J Bond; C Hughes; H D Röher; E D Williams; D Wynford-Thomas
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

6.  Poorly differentiated thyroid carcinomas with primordial cell component. A group of aggressive lesions sharing insular, trabecular, and solid patterns.

Authors:  M Papotti; F Botto Micca; A Favero; N Palestini; G Bussolati
Journal:  Am J Surg Pathol       Date:  1993-03       Impact factor: 6.394

7.  Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.

Authors:  K Yoshimoto; H Iwahana; A Fukuda; T Sano; S Saito; M Itakura
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

8.  Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.

Authors:  T Ito; T Seyama; T Mizuno; N Tsuyama; T Hayashi; Y Hayashi; K Dohi; N Nakamura; M Akiyama
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

9.  Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas.

Authors:  A Sakamoto; N Kasai; H Sugano
Journal:  Cancer       Date:  1983-11-15       Impact factor: 6.860

10.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.

Authors:  J A Fagin; K Matsuo; A Karmakar; D L Chen; S H Tang; H P Koeffler
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

View more
  7 in total

1.  Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.

Authors:  K Y Lam; C Y Lo; K W Chan; K Y Wan
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

Review 2.  Molecular pathobiology of thyroid neoplasms.

Authors:  Giovanni Tallini
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

3.  Expression of p21cip1, p27kip1, and p16INk4a cyclin-dependent kinase inhibitors in papillary thyroid carcinoma: correlation with clinicopathological factors.

Authors:  Carles Zafon; Gabriel Obiols; Josep Castellví; Santiago Ramon y Cajal; Juan Antonio Baena; Jordi Mesa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

4.  p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer.

Authors:  M A Anttila; V M Kosma; J Hongxiu; J Puolakka; M Juhola; S Saarikoski; K Syrjänen
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

5.  Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer.

Authors:  M A Anttila; J K Kellokoski; K I Moisio; P J Mitchell; S Saarikoski; K Syrjänen; V M Kosma
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

6.  Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer.

Authors:  Mei-Chieh Chen; Yuan-Chin Tsai; Jen-Ho Tseng; Jr-Jiun Liou; Steve Horng; Heng-Ching Wen; Yu-Ching Fan; Wen-Bin Zhong; Sung-Po Hsu
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

7.  A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model.

Authors:  Wen-Bin Zhong; Yuan-Chin Tsai; Li-Han Chin; Jen-Ho Tseng; Li-Wen Tang; Steve Horng; Yu-Ching Fan; Sung-Po Hsu
Journal:  Int J Mol Sci       Date:  2018-06-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.